Andres Cubillos-Ruiz

Company: Florey Biosciences

Job title: Co-Founder & Chief Executive Officer

Seminars:

Engineering Probiotics to Safeguard the Gut Microbiome During Antibiotic Therapy 12:00 pm

Impact of Antibiotics on the Gut Microbiome: Exploring how common antibiotic treatments Introduction to FLR-101, an engineered yeast strain designed to produce enzymes that locally degrade specific antibiotics in the gut, thereby managing impacts to the microbiome without compromising the efficacy of the treatment Regulatory Strategy and Medical Food Classification: Discussing Florey's unique approach to…Read more

day: Conference Day Two, Track Two, AM

Panel Discussion: From Consumer Success to Clinical Impact: How Direct-to-Consumer Microbiome Products Are Shaping Therapeutic Breakthroughs 4:30 pm

Evaluating clinical trial strategies for direct-to-consumer microbiome products: costs, regulatory pathways, and scientific credibility Analyzing the economic viability of trial-based models in the DTC space: profitability, investor interest, and commercialization speed Navigating marketing and regulatory constraints for microbiome therapeutics in a consumer-driven landscapeRead more

day: Conference Day One, 14:30 - 18:00